Quantum News
Sign InSign Up
Back to News
research

Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide Transcript

Seeking Alpha
Loading...
2 min read
0 likes
⚡ Quantum Brief
Novo Nordisk revealed top-line Phase III results from REDEFINE 4, a head-to-head obesity trial comparing its experimental dual-hormone drug CagriSema against Eli Lilly’s tirzepatide. CagriSema demonstrated superior weight loss efficacy, with patients achieving a mean reduction of 22.1% versus tirzepatide’s 18.9% over 72 weeks, meeting the trial’s primary endpoint. The trial enrolled 800+ adults with obesity or overweight complications, marking the first direct comparison of these next-gen GLP-1/GIP and GLP-1/amylin therapies in a Phase III setting. Safety profiles were comparable, though CagriSema showed slightly higher gastrointestinal side effects, aligning with its mechanism targeting both appetite and glucose metabolism. CEO Maziar Doustdar called the data a "pivotal milestone," signaling potential market disruption as Novo Nordisk prepares for regulatory filings in late 2026.
AI Audio Summary
0:00 / 0:00
Click to play
dcbb6659-0daf-4a2e-923f-3b6f2f91cf21.jpeg
Quantum News · Media Library

Understand this faster with AI

ChatGPTAsk ChatGPTPerplexityResearch with PerplexityClaudeExplain with ClaudeGrokDiscuss on Grok

SA Transcripts158.56K FollowersFollow5ShareSaveCommentsPlay Earnings CallPlay Earnings Call Novo Nordisk A/S (NOVO:CA) Discusses Top Line Results of REDEFINE 4 Phase III Obesity Trial Comparing CagriSema and Tirzepatide February 23, 2026 5:30 AM EST Company Participants Michael Novod - Senior VP & Head of Investor RelationsMartin Lange - EVP of R&D, Chief Scientific Officer and Member of the Management BoardMaziar Doustdar - President, CEO & Member of the Management Board Conference Call Participants Michael Nedelcovych - TD Cowen, Research DivisionMichael Leuchten - Jefferies LLC, Research DivisionJames Quigley - Goldman Sachs Group, Inc., Research DivisionPeter Verdult - BNP Paribas, Research DivisionHarry Sephton - UBS Investment Bank, Research DivisionEmmanuel Papadakis - Deutsche Bank AG, Research DivisionCarsten Madsen - Danske Bank A/S, Research DivisionMartin Parkhoi - SEB, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the Novo Nordisk conference call. [Operator Instructions] Please be advised that today's conference is being recorded. I would now like to turn the conference over to your first speaker today, Michael Novod, Head of Investor Relations. Please go ahead. Michael NovodSenior VP & Head of Investor Relations Thank you, operator. Good day, and welcome to this Novo Nordisk call regarding the top line results of the REDEFINE 4 Phase III trial. My name is Michael Novod, I'm the Head of Investor Relations at Novo Nordisk. With me today, I have CEO of Novo Nordisk, Mike Doustdar; and EVP, Research and Development and Chief Scientific Officer, Martin Holst Lange. All the speakers will be available for the Q&A session. Please note that this call and Q&A will be related to the top line redefined fall data announced today, and no further details will be discussed. Today's call is being webcasted live, and a recording will be made available on our website. The call is scheduled to last around 30 minutes.

Read Original

Tags

quantum-finance

Source Information

Source: Seeking Alpha

Discussion

0 professional contributions

Sign in to join this professional discussion.

Be the first to add a constructive contribution.